Structural Genomics Consortium
Dr. Aled Edwards is the founder and Chief Executive of the Structural Genomics Consortium (SGC), a research organization celebrated for being a pioneer of open science, particularly as it applies to protein science, chemical biology and drug discovery. Aled leads the six SGC laboratories from the SGC headquarters in Canada.
Aled is a Professor at the University of Toronto and an Adjunct Professor at McGill University. He has published over 200 papers and his teams have contributed over 4,500 structures into the Protein Data Bank, as of 2021. Aled has also founded many companies, including Affinium Pharmaceuticals, which developed a novel antibiotic currently in late-stage clinical trials, and M4K Pharma, the first pharmaceutical company formed explicitly to invent new, and affordably priced, medicines for pediatric cancers.
Structural Genomics Consortium
The SGC catalyzes research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome. The SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in eight global pharmaceutical companies.